The European Commission granted marketing authorization to Zoetis for its monoclonal antibody therapy Portela (relfovetmab) to treat osteoarthritis pain in cats.
Portela is the first long‑acting anti‑nerve growth factor antibody approved for feline OA, providing a three‑month dosing interval that replaces the monthly Solensia regimen.
Zoetis reported Q2 2025 revenue of $2.5 billion, a 4 % year‑over‑year increase, and raised its full‑year 2025 guidance. The company’s 2024 revenue totaled $9.3 billion, with companion‑animal products accounting for the majority of growth. The new approval expands the companion‑animal portfolio and strengthens the biologics segment.
The feline OA market is sizable, with up to 40 % of cats showing clinical signs and only 18 % diagnosed by veterinarians. Portela’s extended dosing interval addresses a significant unmet need and positions Zoetis ahead of competitors such as Elanco and Merck Animal Health, who are also developing biologics for chronic pain.
Management highlighted that the approval underscores Zoetis’s leadership in biologics and its strategy to deliver convenient, long‑acting therapies. The company noted that while some monoclonal antibody products have experienced sales declines in the U.S. due to side‑effect concerns, the long‑acting profile of Portela is expected to improve compliance and market penetration.
Zoetis anticipates commercial availability of Portela in the EU in 2026, following the regulatory approval.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.